A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
| Author | |
|---|---|
| Abstract |
:
Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). |
| Year of Publication |
:
2018
|
| Journal |
:
Journal of hypertension
|
| Date Published |
:
2018
|
| ISSN Number |
:
0263-6352
|
| URL |
:
http://Insights.ovid.com/pubmed?pmid=29334491
|
| DOI |
:
10.1097/HJH.0000000000001647
|
| Short Title |
:
J Hypertens
|
| Download citation |
